Bruton's tyrosine kinase inhibition attenuates disease progression by reducing renal immune cell invasion in mice with hemolytic-uremic syndrome.

In the spleen, ibrutinib-treated mice with HUS showed a trend towards decreased NLRP3 ( Figure 5C ) and pro-IL-1β ( Figure 5D ) expression, while acalabrutinib-treated mice with HUS showed a significantly decreased protein expression of NLRP3 ( Figure 5C ) and pro-IL-1β ( Figure 5D ) compared with vehicle-treated mice with HUS.

also in 53,322 other papers